Setup News Ticker
Searching for 'Stock trade'. (Return)

MarketWatch MarketPulseJun 17, 2019
S&P places Pfizer ratings on CreditWatch negative after $11.4 billion Array deal
S&P Global Ratings placed Pfizer Inc.'s ratings on CreditWatch negative on Monday, after the drug company announced that it is acquiring Array BioPharma Inc. for about $11.4 billion in cash and debt. The move reflects the view "that the company is becoming more tolerant of adjusted net debt leverage slightly greater than 2.0 times," S&P said in a statement. The rating agency is expecting Pfizer's adjusted leverage for 2019 to rise to about 2.5 times because of the deal, up from 1.7 times in 2018, and above S&P's expectation for about 1.6 times in 2019. For now, it expects to lower the company's AA issuer rating by one notch, although it conceded that the deal does have benefits. "We view the transaction as beneficial to Pfizer's business position in the oncology market, as Array BioPharma already has two approved cancer drugs, several royalty generating agreements, a development pipeline with several products, and a highly productive research and development (R&D) engine," it said. Pfizer shares were flat in premarket trade, but have fallen 2% in 2019, while the S&P 500 has gained 15% and the Dow Jones Industrial Average , which counts Pfizer as a member, has gained 12%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

USA Today MoneyJun 17, 2019
Are interest rates going down? Trade war, stock market, vulnerable economy may press Fed
The Federal Reserve is likely to open the door to a possible rate cut in July, depending on U.S.-China trade talks in coming weeks, economists say.       

MarketWatch MarketPulseJun 17, 2019
Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech
Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypoglycemia-prone diabetes resulting from total pancreatectomy, caused by chronic pancreatitis. Orgenesis has an exclusive license for the technology from Israel's Tel Hashomer Medical Research Infrastructure and Services Ltd., that is based on the work of Professor Sarah Ferber, the company's chief scientific officer and a researcher at THM. Patients who have total pancreatectomy always suffer from diabetes, which results in lifelong insulin-dependence with the loss of endogenous insulin secretion and that of the counter-regulatory hormone, glucagon. Shares have fallen 8% in 2019, while the S&P 500 has gained 15%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

BillionHuawei Pfizer Array deal ban
Trumpinterview coughing during Heights CNN
ArrayPfizer BioPharma billion buy cancer
PfizerArray BioPharma billion buy cancer
ChinaUBS tariffs loses bond mandate
dealbillion Iran nuclear Uranium Pfizer
StocksFed meeting watch Array BioPharma
stockFed Market Array BioPharma deal
BuyPfizer Array billion BioPharma stock
BioPharmaArray Pfizer buy billion cancer

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2019 CEOExpress Company LLC